drugset / Trial / NCT06939777
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants
RandomizedSequentialQuadruple-blindPrevention
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the full human anti-tetanus toxin monoclonal antibody SNA02-48 injection and compare the Tetanus-antibody levels and safety of SNA02-48 with human tetanus immunoglobulin (HTIG) in Chinese adult participants.
Timeline
- Start
- 2025-04-28
- Primary completion
- 2025-12-08
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Human tetanus immunoglobulin | Protein / enzyme biologic | — | Intramuscular |
| Subject | SNA02-48 | Monoclonal antibody | — | Intramuscular |
| Subject | tetanus toxoid | Vaccine | — | Intramuscular |